229 active not recruiting. 229 Phase 2, 48 Phase 1, 20 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 229 | Active not recruiting 229 |
| Phase 1 | 48 | Active not recruiting 48 |
| Phase 3 | 20 | Active not recruiting 20 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) mRNA-1982, Placebo - Lyme Disease | Phase 2 | Active not recruiting | ModernaTX, Inc. | 366 | 2026-04-29 | 2026-08-03 |
| Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine Haemophilus influenzae serotype a vaccine candidate, Saline (as a placebo) - Haemophilus Influenzae, Haemophilus Influenzae Type a | Phase 2 | Active not recruiting | InventVacc Biologicals Inc. | 47 | 2026-04-29 | 2026-08-03 |
| Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above Shingrix, CVI-VZV-001 - Herpes Zoster | Phase 2 | Active not recruiting | Aribio Lab Co., Ltd. | 135 | 2026-04-17 | 2026-10-28 |
| A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo - Lyme Disease | Phase 2 | Active not recruiting | Tarsus Pharmaceuticals, Inc. | 722 | 2026-03-09 | 2026-07-09 |
| Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine Recombinant Influenza vaccine candidate, Commercial Influenza vaccine - Influenza | Phase 1 / Phase 2 | Active not recruiting | Aramis Biotechnologies Inc. | 728 | 2026-02-25 | 2026-08-04 |
| Dose Finding Trial of R21/Matrix-M in School Children 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M - Malaria (Plasmodium Falciparum) | Phase 2 | Active not recruiting | University of Oxford | 40 | 2026-02-18 | 2026-08-24 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Abdominal aBscess Catheter Sclerotherapy (ABCS) Catheter Sclerotherapy - Abdominal Abscess | Phase 1 / Phase 2 | Active not recruiting | University of Alabama at Birmingham | 60 | 2025-12-21 | 2026-09-24 |
| This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza TRX-100, Standard of Care (SOC) - Influenza | Phase 2 | Active not recruiting | Traws Pharma, Inc. | 105 | 2025-12-15 | 2026-03-27 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M R21, RH5.1, R78C - Malaria,Falciparum | Phase 2 | Active not recruiting | University of Oxford | 360 | 2025-12-15 | 2026-10-21 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Amgen | 104 | 2025-12-08 | 2026-10-05 |
| Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above ABO1108, Placebo - Varicella-zoster Virus | Phase 2 | Active not recruiting | Suzhou Abogen Biosciences Co., Ltd. | 300 | 2025-11-15 | 2026-05-11 |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Ritlecitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Pfizer | 128 | 2025-11-13 | 2026-10-20 |
| A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102, HT-101 placebo - Chronic Hepatitis B | Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 60 | 2025-11-05 | 2026-10-29 |
| Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine - COVID-19 | Phase 2 | Active not recruiting | CastleVax Inc. | 200 | 2025-11-03 | 2026-07-22 |
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Active not recruiting | Bluefin Biomedicine, Inc. | 210 | 2025-11-03 | 2026-10-14 |
| A Study With CIT-013 in HS Patients CIT-013 high dose, CIT-013 medium dose, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | Citryll BV | 108 | 2025-10-31 | 2026-10-19 |
| The Long COVID Treatment Trial Tirzepatide, Placebo - Long COVID | Phase 2 | Active not recruiting | Scripps Translational Science Institute | 1000 | 2025-10-30 | 2025-12-23 |
| A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) MK-1406 Injection - Healthy Participants | Phase 2 | Active not recruiting | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 400 | 2025-10-29 | 2026-08-20 |
Showing 20 of 229. Sign in to see all of them.
Burkitt Lymphoma (23) · COVID-19 (21) · Carcinoma, Merkel Cell (15) · Hepatitis B, Chronic (14) · Acquired Immunodeficiency Syndrome (11) · HIV Infections (9) · Post-Acute COVID-19 Syndrome (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Hidradenitis Suppurativa (7) · Epstein-Barr Virus Infections (6) · Herpes Zoster (6) · Neoplasms (6) · Pneumonia (6) · Recurrence (6)
Virus Diseases (155) · DNA Virus Infections (84) · RNA Virus Infections (74) · Pathological Conditions, Signs and Symptoms (61) · Pathologic Processes (58) · Immune System Diseases (52) · Respiratory Tract Diseases (51) · Neoplasms (49) · Neoplasms by Histologic Type (49) · Tumor Virus Infections (49) · Communicable Diseases (44) · Respiratory Tract Infections (43) · Bacterial Infections and Mycoses (42) · Herpesviridae Infections (42)
Cyclophosphamide (11) · Specimen Handling (8) · Vincristine (7) · Biopsy (6) · Etoposide (6) · Magnetic Resonance Spectroscopy (6) · Methotrexate (6) · Nivolumab (6) · Prednisone (6) · Saline Solution (5) · Tacrolimus (5) · avelumab (5) · bedaquiline (5) · pembrolizumab (5) · Busulfan (4)
National Cancer Institute (NCI) (11) · GlaxoSmithKline (5) · M.D. Anderson Cancer Center (5) · University of Oxford (5) · Memorial Sloan Kettering Cancer Center (4) · Bavarian Nordic (3) · Merck Sharp & Dohme LLC (3) · ModernaTX, Inc. (3) · Sanofi Pasteur, a Sanofi Company (3) · The Aurum Institute NPC (3) · University of Washington (3) · AIDS Malignancy Consortium (2) · Ausper Biopharma Co., Ltd. (2) · Brigham and Women's Hospital (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2)
United States (134) · Canada (26) · China (26) · Spain (23) · United Kingdom (20) · South Africa (17) · Australia (16) · Germany (16) · France (14) · Italy (13) · Puerto Rico (10) · South Korea (9) · Belgium (8) · Brazil (8) · Taiwan (8)
Brian Ward, MD (2) · Dimana Dimitrova, M.D. (2) · A. Dimitrios Colevas (1) · Abdurakhim Toychiev, PhD (1) · Ahinoam Lev-Sagie (1) · Alexander D Douglas (1) · Alexander Sulakvelidze, PhD (1) · Ali Ellebedy, PhD (1)
PMID 41671463, PMID 35622074, PMID 41586499, PMID 21487108, PMID 24174627, PMID 25331113, PMID 26704020, PMID 27760761, PMID 28390459, PMID 28605006, PMID 29618479, PMID 31270648, PMID 32040960, PMID 32385871, PMID 32493473, PMID 32589970, PMID 32600259, PMID 32633595, PMID 33049057, PMID 33127750, PMID 33720337, PMID 33730519, PMID 33750072, PMID 33977284, PMID 34233965, PMID 34473343, PMID 34677696, PMID 34699271, PMID 34746723, PMID 34815288, PMID 34992881, PMID 35007127, PMID 35105560, PMID 35389428, PMID 35507508, PMID 35507536, PMID 35562576, PMID 35562778, PMID 35601423, PMID 35950603, PMID 35998741, PMID 36027906, PMID 36239787, PMID 36322825, PMID 36345941, PMID 36733569, PMID 36883141, PMID 37146874, PMID 37154608, PMID 37269870
2023 (7), 2025 (3), 2018 (2), P30CA015704 (2), P30CA033572 (2), U10CA180820 (2), U10CA180888 (2), UM1CA121947 (2), UM1CA186709 (2), 2014 (1), 2016 (1), 2017 (1), 2019 (1), D43TW012274 (1), N01CN00035 (1)